In 1943, the name penicillamine was given to an amino acid BB-dimethylcysteine found among the acid penicillin hydrolysates (Abraham et al. 1943) . It is now 21 years since J M Walshe first gave penicillamine to a patient with Wilson's disease (Walshe 1956 ). In the intervening years, penicillamine has found a place in the treatment of many diseases, including Wilson's disease, cystinuria (Crawhall et al. 1963) , lead poisoning (Boulding & Baker 1957) , and morphea (Moynahan 1973) . It has been tried in many other diseases, sometimes with promising results, such as chronic active hepatitis (Stern et al. 1976 ), primary biliary cirrhosis (S Jain 1976, personal communication), and scleroderma (Bluestone et al. 1970) . The drug has a variety of biological effects and it is evident that exploration of other applications may prove fruitful., Initially penicillamine was used in rheumatoid arthritis because it dissociates certain macroglobulins in vitro (Deutsch & Morton 1957) . Evidence of its clinical efficacy was first published in 1964 (Jaffe 1964). In the next nine years the reports of many workers in uncontrolled studies (Zuckner et al. 1970 , Huskisson & Hart 1972 , confirmed this initial report. It was not until the Multicentre Trial Group published its results in 1973, that penicillamine was clearly shown to be effective in rheumatoid arthritis. This trial, which used a predetermined and rather high dose of penicillamine, compared its effect in 52 patients with severe uncontrolled rheumatoid disease with that of placebo capsules in 53 similar patients. The results of the trial were remarkably favourable in terms of improvement in clinical features, but the number of side-effects was prohibitive and 16 of the treatment group were withdrawn from the trial because of adverse reactions. The harsh realities of this first controlled trial have been tempered somewhat by later work. Penicillamine and gold have been shown to be equipotent in another Multicentre trial (Huskisson et al. 1974) . In this study penicillamine possibly had the edge over gold, because fewer patients on penicillamine were withdrawn permanently. Penicillamine and azathioprine are probably also equally effective (H Berry 1976, personal communication) . The introduction of the so-called 'go slow, go low' dosage schedule has shown that more widely spaced increments and a lower maximum dose lead to fewer sideeffects (Eighth European Rheumatology Congress 1975, abstracts; Day 1974) . No dosage regime has, however, lowered the incidence of proteinuria.
Wilson's disease and cystinuria are lifethreatening conditions. The benefits of penicillamine in the treatment of these diseases easily outweigh its adverse effects. Rheumatoid arthritis, although incurable, painful, and sometimes crippling, is only rarely a fatal disease. It is clear that the introduction of a new long-term treatment for rheumatoid arthritis, with many toxic and sometimes potentially fatal side-effects, must be slow and cautious. Since the publication of the first controlled trial in rheumatoid arthritis, physicians and scientists interested in penicillamine have met annually to discuss the latest advances in treatment. These meetings have provided a forum for the frank exchange of information about the drug. The pooling of knowledge about side-effects and dosage regimes in particular has meant that penicillamine is still not widely used in the United Kingdom, and, perhaps, that some fatal drug reactions have been prevented. It is essential that this cautious approach to the use of the drug should continue, for pencillamine is not a routine treatment for rheumatoid arthritis, its mode of action is unknown, and there is as yet no published evidence that it prevents long-term changes in affected joints.
All rheumatologists would agree that the initial treatment of rheumatoid arthritis should be simple and be based on analgesic, anti-inflammatory drugs, rest and splints. The chance of spontaneous remission in this group of patients is high in the first year or two of the disease and the majority of patients will be comfortable and able to lead a normal life by the end of this time. Where the disease follows a remorselessly aggressive course and encroaches increasingly on the patient's daily life, alternative treatment is indicated. The choice of treatment lies between gold, antimalarials, immunosuppressive drugs, and now penicillamine. Immunosuppressive drugs are on the whole less widely used than the other drugs. Antimalarial drugs are not so effective as gold or penicillamine, but their use is more easily controlled and serious side-effects are few. Some patients will respond to antimalarial drugs very well. Provided that ophthalmological control is available, some clinicians Proc. roy. Soc. Med. Volume 70 February 1977 would put all the patients requiring long-term treatment on to these drugs for an initial period of three months. Patients who do not respond would then be considered for gold or penicillamine.
There is no way at present of predicting the response to either gold or penicillamine. The choice of drug will depend upon local and personal factors, such as the availability of appropriate back-up services, the clinician's personal experience of the drugs, a previous history of drug rashes, eczema or penicillin sensitivity, and the patient's preference as between tablets and injections. Neither treatment should be embarked upon without adequate laboratory facilities for hmmatological and biochemical monitoring of side-effects.
The optimum dose of penicillamine has not yet been determined. The regime followed in the Multicentre Trial was an incremental dosage over ten weeks to a total of 1.5 g. Since then further experience has led to a gradual lowering of the total daily dose and an increase in the time scale for increments. At present most clinicians start the patient on 250 mg daily and introduce the first increment of 250 mg only after eight weeks. Further increments are made even more slowly and it is seldom necessary to exceed 750 mg daily, except in the severer and more longstanding cases. Some patients do remarkably well on only 125 mg daily. It is sometimes possible to scale down the dose by similar decrements after one year of continuous treatment. The aim of treatment should be to cut out all other drugs except occasional analgesics by the end of the first year of treatment. It has not so far proved possible to stop treatment without an eventual relapse. Further work is continuing to determine whether a single daily dose of 250 mg between meals is sufficient for the majority of patients (I A Jaffe 1976, personal communication).
As with all drugs, frequent monitoring of patients is essential, and should be carefully explained before embarking on treatment. Weekly blood and urine tests are required initially, with full platelet and differential white blood counts. After four weeks such monitoring can be carried out at fortnightly intervals. Once the patient is stabilized on his maximum dose, tests can be carried out at monthly visits, provided that the patient will undertake to test his own urine weekly for blood and protein. Three monthly biochemical tests of renal function are also required. It is important that the results of all tests are scrutinized personally by the physician and not filed routinely. With such careful monitoring any side-effects should be quickly reversible.
The initial side-effects of penicillamine, apart from rare cases of bone-marrow idiosyncrasy, are unpleasant but reversible and are not serious. These include nausea, vomiting, rash, dysgeusia or ageusia, and indigestion. Except in a few patients with vomiting, most of the effects will disappear and the patient should be encouraged to soldier on with the drug. A variety of other rarer but important side-effects has now been encountered with wider use of penicillamine. Some require immediate cessation of the therapy, some merely a lowering of the dose. Such effects include a lupuslike reaction (Day & Golding 1974) , mammary hyperplasia, hemolytic anemia, bone marrow aplasia, mouth ulcers, Goodpasture's syndrome, myasthenia gravis, late rashes, hirsutism and polymyositis. Seven fatalities directly attributable to the drug have been reported, and more cases will undoubtedly arise.
The two most common and potentially serious side-effects are thrombocytopenia and proteinuria, which are met with in about 30 % of patients who are able to tolerate penicillamine for more than six months. Fortunately there is usually ample warning of their development, namely a gradual slide in the platelet count to bel6w 100 000 and a gradual increase in proteinuria to above 2 g per day. Both these levels are regarded by clinicians as the cut-off point for withdrawal of therapy. It is sometimes possible to stave off this necessity by cutting the daily dose when these side-effects first appear. Thrombocytopenia is usually quickly reversed on withdrawal of the drug, which can then sometimes be introduced at a much lower dosage. Proteinuria disappears more slowly, over the next one to two years. There have been reports of proteinuria disappearing while the drug was continued, but most clinicians would not advocate this, and few have so far restarted patients on the drug who have previously experienced this side-effect.
The mode of action of penicillamine is unknown and its absorption and metabolism poorly understood. There is recent evidence that it is well absorbed from the empty stomach (I A Jaffe 1976, personal communication), and that other drugs such as iron may interfere with its mode of action. It is excreted as a number of metabolites fairly rapidly, but some of the drug is tissue bound very strongly and is excreted only slowly over many months. The idea that penicillamine acts because of its action on macroglobulins is now discounted. It is not an immunosuppressive drug (Huskisson & Berry 1974) . It has no effect on adjuvant arthritis in the rat (Liyanage & Currey 1972) . Penicillamine inhibits certain viruses in vitro (Lodde & Marcialis 1974) . There is no evidence that its chelating effect on various metals bears any relationship to its clinical effect in rheumatoid arthritis.
Although penicillamine now has an established place in the treatment of rheumatoid arthritis, more widespread use of the drug in recent years has highlighted rather than diminished its many adverse effects. It remains a difficult drug to use, requiring careful monitoring and frequent visits by the patient to the clinician. There is certainly no place for further extension of its use at present. Any doctor wishing to use it must be prepared to commit himself to the exacting and timeconsuming supervision of the patient which may have to be continued for many years. If there is any doubt about the availability of spegialist back-up care, or the willingness of the patient to attend for regular tests, this treatment should not be started. On the evidence available at present it would be wise to adopt only the treatment regime of a low starting dose with graduated increments to a low maximum dose. Penicillamine treatment for rheumatoid arthritis is undoubtedly an advance but one tempered with many difficulties.
